Tocilizumab for rheumatoid arthritis
JA Singh, S Beg… - Cochrane database of …, 2010 - cochranelibrary.com
JA Singh, S Beg, MA Lopez‐Olivo
Cochrane database of systematic reviews, 2010•cochranelibrary.comBackground Tocilizumab, a new biologic that inhibits interleukin‐6, is approved for treatment
of rheumatoid arthritis (RA) in Europe, Japan and the US. Objectives To assess the efficacy
and safety of tocilizumab in patients with RA using the data from published randomized or
quasi‐randomized controlled trials (RCTs).
of rheumatoid arthritis (RA) in Europe, Japan and the US. Objectives To assess the efficacy
and safety of tocilizumab in patients with RA using the data from published randomized or
quasi‐randomized controlled trials (RCTs).
Background
Tocilizumab, a new biologic that inhibits interleukin‐6, is approved for treatment of rheumatoid arthritis (RA) in Europe, Japan and the US.
Objectives
To assess the efficacy and safety of tocilizumab in patients with RA using the data from published randomized or quasi‐randomized controlled trials (RCTs).
cochranelibrary.com